Skip to main content
. 2020 Jul 31;7:363. doi: 10.3389/fmed.2020.00363

Table 3.

Comparison of MSAs/MAAs between IIM patients with RP-ILD and C-ILD.

Variables RP-ILD n = 82 C-ILD n = 125 P-value
MYOSITIS-SPECIFIC ANTIBODIES
Anti-synthetase antibodies (+), no. (%) 35 (42.7) 71 (56.8) 0.047*
Anti-Jo-1, no. (%) 11 (13.4) 40 (32.0) 0.002*
Anti-MDA5, no. (%) 32 (39.0) 15 (12.0) 0.000*
Anti-Mi-2, no. (%) 2 (2.4) 3 (2.4) 1.000
Anti-TIF1-γ, no. (%) 3 (3.7) 4 (3.2) 1.000
Anti-NXP2, no. (%) 2 (2.4) 4 (3.2) 1.000
Anti-SAE, no. (%) 2 (2.4) 3 (2.4) 1.000
MYOSITIS-ASSOCIATED ANTIBODIES
Anti-Ro-52, no. (%) 48 (58.5) 51 (40.8) 0.012*
Anti-PM/Scl-75/100, no. (%) 8 (9.8) 15 (12.0) 0.615
Anti-Ku, no. (%) 3 (3.7) 7 (5.6) 0.743
*

< 0.05. IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease; RP-ILD, rapidly progressive ILD; C-ILD, Chronic ILD. ARS include EJ, OJ, PL-7, PL-12, KS. ARS, aminoacyl-tRNA synthetase; MDA5, melanoma differentiation-associated 5; TIF-1γ, translation initiation factor-1a; NXP2, nuclear matrix protein 2; SAE, small ubiquitin-like modifier enzyme; PM/Scl, polymyositis/scleroderma.